 Sydney, AUSTRALIA, Dec. 10, 2020 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune diseases, is pleased to announce that its Chinese partner, EOC Pharma will commence a new Phase II clinical trial in up to 152 metastatic breast cancer patients in China. 